Convertible Instruments Under Cayman Law: SAFEs, Convertible Notes, and Investor Protection

This article examines how convertible instruments — SAFEs, convertible notes, and hybrid instruments — work under Cayman law, the statutory framework governing their characterisation as equity or debt instruments, conversion mechanics and valuation mechanics, the interaction with Cayman company law provisions regarding share issuance and pre-emption rights, and practical considerations for founders and investors structuring early-stage financing through Cayman entities.

SAFEs and Convertible Notes: Structural Similarities and Key Differences

A SAFE (Simple Agreement for Future Equity) is a contractual instrument developed by Y Combinator and has become ubiquitous in seed-stage financing, particularly in the technology sector. A SAFE is not a debt instrument; it is a contractual commitment by the company to convert the investor's contribution into equity at a future event (typically the next priced equity round). The investor contributes capital to the company in exchange for a SAFE that grants the investor the right to receive future equity at a specified conversion rate determined by a valuation cap and a discount rate.

By contrast, a convertible note is a debt instrument issued by the company that is obligated to be repaid with interest unless and until conversion occurs. A convertible note has a maturity date, a specified interest rate, and explicit conversion terms. If conversion does not occur by the maturity date, the note is repaid with interest. This distinction is legally significant: a SAFE is not a debt instrument (and therefore does not trigger the company's debt reporting or covenant obligations), while a convertible note is a debt instrument.

The practical difference is substantial. A company issuing SAFEs to ten different investors has received capital but has no debt obligations, no interest accrual, and no maturity dates. By contrast, a company issuing convertible notes to the same investors has ten separate debt obligations, each of which must be tracked, for which interest must accrue, and each of which must be managed in the context of other debt instruments and loan covenants. For a cash-constrained startup, avoiding the administrative and financial burden of tracking convertible note debt is attractive, making SAFEs increasingly popular.

However, from an investor protection perspective, a convertible note offers more explicit protection than a SAFE. A convertible note specifies the circumstances under which the note is repaid with interest (e.g., if the company achieves a specified revenue milestone but does not raise a priced equity round, or if the company is acquired at a valuation below a specified threshold). A SAFE does not specify what happens if conversion is never triggered; the investor's rights are contingent on a conversion event occurring, with no fallback to repayment or other exit rights. This difference has become more pronounced as the venture market has evolved: early-stage investors increasingly push back on SAFEs and demand the greater protection offered by convertible notes.

A third instrument, increasingly used alongside or instead of SAFEs, is the convertible equity note or "post-money SAFE." This instrument attempts to combine the simplicity of a SAFE with greater investor protection by explicitly addressing the investor's rights if no conversion event occurs and by clarifying the mathematical treatment of the conversion in the context of subsequent equity issuances. Post-money SAFEs and convertible equity notes have become more complex than the original simple SAFE, sometimes requiring as much documentation as a traditional convertible note.

Legal Characterisation Under Cayman Law: Equity vs. Debt

The legal characterisation of a SAFE or convertible note under Cayman law affects multiple aspects of company governance and investor rights. The key question is whether the instrument is characterised as equity (a share or right to acquire shares in the company) or as debt (a promissory obligation).

Under Cayman law, a SAFE is not, by its terms, an equity instrument. The SAFE grants the investor a contractual right to receive future equity at a conversion event, but the investor does not hold equity until conversion occurs. This has several consequences:

1. the investor does not have voting rights in the company until conversion (since the investor is not a shareholder);
2. the investor is not entitled to receive dividends declared by the company until conversion;
3. the investor's claim against the company is contractual, not based on share ownership; and
4. the investor's claim ranks with other unsecured creditors in a liquidation, rather than with shareholders (unless the SAFE specifies otherwise).

A convertible note is explicitly a debt instrument, creating a debtor-creditor relationship between the company and the note holder. The note holder has contractual rights to repayment of principal and interest, and the note holder's claim ranks ahead of equity holders in a liquidation. However, the conversion feature transforms the note from debt into equity at a specified event.

The interaction between Cayman company law and convertible instruments creates ambiguities. The Companies Act (2023 Revision) provides for the issuance of shares and specifies that shares must be issued in accordance with the company's memorandum and articles of association. The conversion of a SAFE or convertible note into shares requires that the shares be validly issued under the Companies Act. However, if the SAFE or note does not specify the valuation at which conversion occurs (or if the valuation is determined by a formula or by reference to a future event), the determination of the number of shares to be issued upon conversion may be uncertain. For example, a SAFE with a "valuation cap" of $10 million specifies that conversion will occur at a price per share determined by dividing the SAFE amount by the valuation cap, without regard to the actual valuation negotiated in a subsequent priced round. However, if no subsequent priced round occurs and the valuation cap is the conversion mechanism, the company must determine the number of shares to issue, which may require a board resolution determining the share price.

The Cayman Courts have not extensively addressed the characterisation of SAFEs or convertible notes, and there is therefore limited domestic case law clarifying their treatment. In practice, Cayman companies and their counsel treat SAFEs and convertible notes as contractual instruments that create contingent obligations to issue shares upon specified events, and the conversion is effectuated through a board resolution and share certificate issued in accordance with the Companies Act. However, the absence of explicit Cayman statutory guidance creates ambiguity, particularly if a dispute arises regarding the proper valuation or share count upon conversion.

Conversion Mechanics: Valuation Caps, Discount Rates, and Pro Rata Rights

The economic terms of a SAFE or convertible note are primarily defined by two mechanics: the valuation cap and the discount rate. These terms determine the conversion price (the price per share at which the investor receives equity upon conversion).

The valuation cap specifies a maximum valuation at which the investor's SAFE or note will convert. For example, a SAFE with a $10 million valuation cap grants the investor the right to convert at a share price determined by dividing the SAFE investment amount by the valuation cap. If an investor contributes $200,000 and the valuation cap is $10 million, the investor receives 200,000 ÷ 10,000,000 = 2 per cent of the fully diluted post-conversion capitalization (subject to adjustment for other conversion events). The valuation cap protects the investor by ensuring that if the company's valuation increases, the investor's conversion price decreases, maximizing the investor's share count upon conversion.

The discount rate specifies a percentage reduction (commonly 20 to 30 per cent) to the share price negotiated in the subsequent priced round. For example, if a subsequent Series A round values the company at $50 million and negotiates a price per share of $5, and the SAFE specifies a 20 per cent discount, the SAFE investor converts at a price of $4 per share (20 per cent discount to the $5 Series A price). The discount rate advantages early investors by giving them a lower conversion price than subsequent investors.

The interaction between valuation cap and discount rate creates complexity. If a company has a Series A round at a valuation below the SAFE's valuation cap, the investor's conversion price is determined by the lower of (a) the Series A share price with discount applied, or (b) the Series A share price using the valuation cap. Most SAFEs specify that the conversion price is the more favourable of these two calculations, meaning the investor receives the benefit of whichever mechanism produces a lower conversion price.

Pro rata rights grant the investor the right to participate in subsequent equity rounds at a price equivalent to existing shareholders, to maintain the investor's ownership percentage. Pro rata rights are typically exercised in Series A and subsequent rounds and are valuable to early investors who wish to maintain their ownership stake as the company raises additional capital. However, pro rata rights create complexity in share issuance planning: if a SAFE investor with pro rata rights invests in each subsequent round to maintain its ownership percentage, the company's capitalization table becomes increasingly complex, with multiple investor cohorts at different share prices and with different rights.

Most SAFEs do not explicitly grant pro rata rights; the Y Combinator standard SAFE form omits pro rata rights entirely. However, many early-stage investors push back and demand pro rata rights through side agreements or amendments to the SAFE. The interaction between a SAFE (which specifies conversion at the Series A valuation cap or discount) and pro rata rights (which grant participation rights in Series B and later rounds) must be carefully documented to avoid ambiguity regarding when pro rata rights are exercised and at what conversion price.

MFN (most-favoured-nation) provisions are increasingly included in SAFEs and convertible notes. An MFN provision grants the investor the right to receive terms no less favourable than any other SAFE or convertible note investor. For example, if an early investor accepts a 30 per cent discount rate and later a subsequent investor negotiates a 25 per cent discount rate, the MFN provision in the early investor's SAFE entitles the early investor to the more favourable 25 per cent rate. MFN provisions protect early investors from the risk that the company will make subsequent offers at better terms, but they create significant complexity and administrative burden for the company in tracking and updating terms across multiple SAFE or convertible note instruments.

Interaction with Cayman Company Law: Share Issuance and Pre-Emption Rights

The conversion of a SAFE or convertible note into shares must comply with the Cayman Islands Companies Act (2023 Revision), which establishes the statutory framework for share issuance.

First, the company must have authorised share capital (shares authorised for issuance by the memorandum and articles of association) sufficient to accommodate the shares to be issued upon conversion. If the company was incorporated with limited authorised capital and multiple SAFEs have been issued, the aggregate conversion could exceed the authorised capital, requiring the company to amend its memorandum to increase authorised shares before conversion can occur. This is a commonly overlooked issue that can delay conversions.

Second, the Companies Act provides that shares issued by a company must be issued in accordance with the company's articles of association. Most Cayman company articles permit the board of directors to issue shares without shareholder approval (unlike UK company law, which typically restricts the board's authority to issue shares and requires shareholder authorization). However, the articles may specify that shares can be issued only at a price determined by the board or approved by shareholders. A SAFE or convertible note that specifies a conversion price determined by a formula (valuation cap divided into investment amount) may raise the question whether that price is a price determined by the board or whether it violates the articles.

Third, and most importantly, pre-emption rights. Cayman company law does not provide for statutory pre-emption rights (unlike UK company law, which provides that shares must be offered to existing shareholders before being issued to non-shareholders). However, a company's articles of association may include pre-emption rights provisions, which would prohibit the board from issuing shares to new investors without first offering the shares to existing shareholders on equivalent terms. If a Cayman company has included pre-emption rights provisions in its articles (a common practice to protect existing shareholders from dilution), and a SAFE is subsequently issued to a new investor that converts into shares, the conversion may technically violate the pre-emption rights provisions, entitling existing shareholders to demand that the new shares be issued to them first (at the conversion price) rather than to the SAFE investor.

This pre-emption rights issue has created substantial disputes in practice. A company that issued SAFEs with valuation caps and discount rates and subsequently receives pre-emption rights invocations by existing shareholders faces a complex situation: if it honors the pre-emption rights and issues the shares to existing shareholders at the SAFE conversion price, the SAFE investor's conversion is blocked. If it attempts to convert the SAFE despite pre-emption rights invocation, the pre-emption rights holders may claim breach of their rights and bring legal action.

The solution is to carefully document the interaction between SAFEs/convertible notes and the company's articles of association. Companies that plan to issue SAFEs should either (1) eliminate or limit pre-emption rights provisions from the articles, or (2) obtain a waiver of pre-emption rights from existing shareholders before issuing SAFEs. Some companies include in their articles a specific waiver of pre-emption rights for SAFE conversions, confirming that pre-emption rights do not apply to shares issued upon SAFE conversion.

Additionally, the share issuance procedures in the Companies Act require that shares be evidenced by a share certificate issued by the company. Conversion of a SAFE into shares should be documented by a board resolution authorising the issuance of shares upon conversion, and should be followed by the issuance of a share certificate to the investor. The absence of a share certificate can create disputes regarding whether conversion has legally occurred and whether the investor is a registered shareholder entitled to voting rights and dividend participation.

Cap Table Management and Dilution Consequences

The proliferation of SAFEs and convertible notes in early-stage companies creates significant challenges in cap table (capitalization table) management. A typical early-stage company might have the following cap table: founder shares (representing the founding team's equity ownership), preferred shares issued to early angel investors in a Series Seed round, and multiple SAFEs or convertible notes issued in a pre-Series A financing round. As the company raises subsequent rounds (Series A, Series B), existing SAFE and convertible note investors convert into shares, the cap table expands with new investor cohorts, and the ownership percentages of existing investors are diluted.

For founders, the dilution resulting from multiple SAFE rounds is material and often underestimated. A founder with 70 per cent ownership after a Series Seed round issuing Series Seed shares to friends and family might subsequently issue $2 million in SAFEs at a $5 million valuation cap. When the next Series A round values the company at $20 million and raises $5 million, the SAFE investors convert at a price determined by the valuation cap (receiving $2 million ÷ $5 million = 40 per cent additional ownership on fully diluted basis after Series A conversion). The dilution can be substantial, and many founders are surprised by the cumulative impact of multiple SAFEs when they convert.

Cayman-domiciled companies should implement rigorous cap table management procedures, including the following:

1. a cap table spreadsheet or software that tracks all issued and convertible securities, with mathematical models showing dilution scenarios (what happens when each SAFE converts at various potential Series A valuations);
2. documentation for each SAFE or convertible note that clearly identifies the conversion terms, the conversion price mechanics, and the anticipated post-conversion ownership percentage;
3. regular (quarterly or semi-annual) cap table updates to ensure that all conversions, stock option exercises, and other dilutive events are reflected; and
4. disclosure to investors and board members showing the fully diluted capitalization reflecting all SAFE and convertible note conversions at anticipated conversion prices.

Failure to implement rigorous cap table management has led to disputes where investors claim that they were not adequately informed of dilution, where SAFEs convert at different prices that are inconsistent with what investors understood, and where the cap table is discovered to be internally inconsistent (shares added up to more than 100 per cent of the company). For a Cayman-domiciled company, cap table disputes can involve multiple jurisdictions (if investors are based in different countries) and multiple legal regimes (Cayman law governing the company's obligations, but investor rights potentially governed by English law if the SAFEs reference English law, or New York law if investors are US-based).

Investor Protection Mechanisms: Down-Round Provisions and Liquidation Preferences

Early-stage investors increasingly demand explicit protection against company valuation decreases (down-rounds) and against liquidation at valuations below their conversion price. These protections are documented through anti-dilution provisions and liquidation preference mechanisms.

Anti-dilution provisions specify how the investor's conversion price is adjusted if the company issues shares at a valuation lower than the investor's conversion price. For example, if a SAFE investor has a valuation cap of $5 million and the company subsequently raises a Series A at a $3 million valuation, the $3 million valuation is below the SAFE's valuation cap, and anti-dilution provisions typically provide that the SAFE investor receives additional shares to compensate for the down-round. There are two principal anti-dilution mechanisms:

1. "full ratchet" anti-dilution, which provides that the SAFE investor's conversion price is reduced to match the down-round price (meaning the investor receives additional shares to maintain the same dollar amount invested); and
2. "weighted average" anti-dilution, which adjusts the conversion price based on a formula reflecting the relative sizes of the down-round and the original commitment.

A SAFE agreement typically does not include explicit anti-dilution provisions; the SAFE's protection is the valuation cap, which ensures that even if the company is valued at a lower amount in a Series A, the investor's conversion price is capped at the valuation cap level. However, if no Series A occurs and the company eventually raises an emergency down-round financing at a much lower valuation, the SAFE investor may receive no explicit protection and may face substantial dilution.

Liquidation preferences specify the order in which investors are paid in a liquidation scenario (including an acquisition or sale of the company). A "1x non-participating preferred liquidation preference" provides that the investor receives their original investment amount before common shareholders (founders and employees) receive anything. A "participating preference" provides that the investor receives their preference (1x or a multiple) and then also participates in the remaining proceeds as if they held common stock (a "double dip" scenario). Liquidation preferences are typically included in Series A and later round agreements, but early-stage SAFE agreements do not typically include explicit liquidation preferences.

The absence of explicit liquidation preferences in SAFEs creates ambiguity regarding what happens if the company is acquired at a valuation below the investor's cost basis. An investor who contributed $500,000 to a SAFE with a $10 million valuation cap expects to receive equity worth at least $500,000 upon conversion. However, if no Series A occurs and the company is acquired for $3 million, the SAFE holder's claim against the $3 million proceeds is unclear. Is the SAFE holder a preferred creditor (ahead of common shareholders), or does the SAFE convert into common shares (putting the SAFE holder in the same position as founders)? The SAFE agreement should explicitly address this scenario.

Cayman company law does not provide explicit guidance on liquidation preferences or the ranking of different share classes in a liquidation. The treatment depends on the company's articles of association and the specific terms of the SAFE or convertible note. Best practice is to include explicit liquidation preference language in each SAFE or convertible note, specifying whether the investor's claim is preferred or pari passu with common shareholders in a liquidation.

Tax Considerations and Implications for Founders and Investors

The tax treatment of SAFEs and convertible notes affects both the company and the investors, and varies significantly depending on the jurisdiction of the investor and the company's home tax regime.

For a Cayman-domiciled company, the issuance of a SAFE or convertible note has minimal Cayman tax consequences. Cayman does not tax companies on the issuance of securities or on the conversion of convertibles into shares. However, tax consequences may arise in the investor's home jurisdiction.

For a US investor, the US Internal Revenue Service (IRS) has issued guidance (Revenue Ruling 2021-26) clarifying that a SAFE is not treated as a debt instrument for federal tax purposes, and that conversion into shares does not trigger a taxable event (the investor's conversion is treated as receiving shares without intermediate income recognition). However, the discount granted to the SAFE investor upon conversion may have tax implications: if the SAFE converts at a price significantly below fair market value, the discount might be treated as additional compensation to the investor or as a gift. The application of this principle depends on the investor's relationship to the company (employee vs. third-party investor).

For founders who issue shares to themselves and then issue SAFEs or convertible notes to investors, the treatment of founder shares can have substantial tax consequences. In the US, founders who contribute assets or services to a company in exchange for founder shares may be subject to income tax on the value of the shares received (if the shares are not subject to substantial restrictions). This "founder tax" is a material concern for early-stage companies and should be managed through a qualified 83(b) election (in the US) or equivalent tax planning in other jurisdictions.

For UK investors, the tax treatment of a SAFE or convertible note depends on the investor's status (individual or corporate investor) and the company's jurisdiction. A UK-resident individual investor contributing to a SAFE in a non-UK company may be subject to UK income tax on any discount granted upon conversion (if the discount is substantial) and may be liable to capital gains tax upon a subsequent exit. Alternatively, the SAFE investment might qualify for the UK Enterprise Investment Scheme (EIS) or Seed Enterprise Investment Scheme (SEIS) if the investment meets the criteria, which would provide tax relief to the investor.

These tax considerations should be evaluated early in the fundraising process, and founders should engage with tax counsel qualified in both the company's jurisdiction (Cayman) and the investors' jurisdictions to optimise tax outcomes.

Practical Drafting Considerations and Common Disputes

The Y Combinator SAFE has been widely adopted as a template, and many early-stage companies use the SAFE form without substantial modification. However, the SAFE's simplicity can obscure important economic and legal issues that frequently give rise to disputes.

First, the SAFE does not specify what happens if no conversion event occurs. The original SAFE language specifies conversion upon certain triggering events (Series A priced round, acquisition, or dissolution), but does not provide fallback rights if none of these events occurs within a specified period. For example, if a company issues a SAFE but then fails to raise a Series A for five years while remaining operational, does the SAFE investor have any rights? Can the investor force a liquidation? Can the investor demand that the company buy back the SAFE investment? The SAFE form does not address these scenarios, creating uncertainty and potential disputes.

Many investors now demand that SAFEs include explicit expiration dates (e.g., "the SAFE expires three years from issuance, and if no conversion event has occurred, the investor has the right to require the company to repurchase the SAFE investment or to convert the SAFE into preferred shares") or automatic conversion mechanisms (e.g., "if no Series A has closed by [date], the SAFE automatically converts into preferred shares at the valuation cap price").

Second, the SAFE does not address the treatment of the investment in connection with subsequent dilutive events (stock splits, recapitalizations, mergers). If the company executes a stock split or a recapitalization that reduces the number of shares outstanding, does the SAFE's valuation cap remain fixed, or is it adjusted proportionally? The SAFE form does not specify, creating ambiguity.

Third, the SAFE does not address the investor's rights to information and governance participation. The investor has committed capital but has no contractual right to receive financial statements, no right to attend board meetings, and no governance participation rights. For many investors, this is an unacceptable omission, and investors push back by demanding information rights (quarterly or annual financial statements) and potentially observer rights (right to attend board meetings).

Fourth, the interaction between multiple SAFEs and the cap table can give rise to disputes regarding anti-dilution protection and the calculation of conversion prices when multiple SAFEs convert simultaneously. If a company has issued three SAFEs with different valuation caps ($5 million, $10 million, $15 million) and subsequently raises a Series A at a $12 million valuation, all three SAFEs convert simultaneously at different conversion prices (the first at the $5 million cap, the second at the $10 million cap, the third at the $12 million Series A price). The mathematical calculation of shares outstanding and post-conversion ownership percentages can be complex, and discrepancies between the investors' expectations and the company's calculations have led to disputes.

These common disputes are best avoided through careful drafting and amendment of SAFE forms to address founder and investor concerns explicitly. For Cayman-domiciled companies, the SAFE should be amended to include:

1. explicit expiration and conversion triggers;
2. treatment of dilutive corporate actions;
3. information rights for the investor;
4. explicit anti-dilution provisions if multiple SAFEs are outstanding; and
5. confirmation that the SAFE conversion is not subject to pre-emption rights (if the company's articles include pre-emption rights).

Regulatory Considerations and CIMA Guidance

The Cayman Islands Monetary Authority (CIMA) has not issued specific guidance on the regulatory treatment of SAFEs or convertible notes in Cayman-domiciled companies. SAFEs and convertible notes are not securities in the traditional sense (they are not traded on securities exchanges and are not offered to the public), so they do not trigger most CIMA regulatory requirements.

However, if a Cayman-domiciled company raises capital through SAFEs or convertible notes and the company is itself a fund or investment vehicle subject to the Private Funds Act 2020, the company may have reporting obligations regarding the capital raised and the use of proceeds. Additionally, if the company issues convertible notes to a substantial investor base and subsequently converts those notes into shares, the issuance and conversion must comply with Cayman companies law, and the company must update its share registry and issue share certificates to converted note holders.

Cayman-domiciled companies should confirm their regulatory status (whether they are classified as private funds or investment vehicles requiring CIMA registration) and should ensure that SAFE and convertible note issuances do not trigger unexpected regulatory obligations or classification changes.

Conclusion and Practical Implications for Founders and Investors

SAFEs and convertible notes have become ubiquitous in early-stage venture financing, providing a mechanism for early capital raising without immediate valuation negotiations. For Cayman-domiciled companies, SAFEs and convertible notes can be issued and converted effectively within the Cayman legal framework, but several issues require explicit attention in drafting and management.

The legal characterisation of SAFEs as non-debt contractual instruments (rather than equity or traditional debt) has advantages (simplicity, no interest accrual, no repayment obligations) but also creates ambiguities regarding investor rights if conversion is never triggered or if the company enters liquidation.

The interaction between SAFEs and Cayman company law provisions (share authorization, pre-emption rights, articles of association) requires careful attention in drafting and in the share conversion process. Companies that plan to issue SAFEs should amend their articles (if necessary) to eliminate or waive pre-emption rights for SAFE conversions, and should implement rigorous cap table management procedures to track all convertible instruments and model dilution scenarios.

Investor protection mechanisms (valuation caps, discount rates, anti-dilution provisions, liquidation preferences, information rights) should be explicit rather than implicit in SAFE and convertible note agreements. The proliferation of "simplified" SAFEs that omit these provisions has led to disputes when investors' expectations regarding protection do not match the contractual provisions.

For Cayman-domiciled companies with international investor bases, careful attention to tax implications (US PFIC treatment, UK EIS/SEIS eligibility, founder share taxation) can significantly affect investor returns and founder incentives.

The most successful early-stage companies establish clear procedures for SAFE issuance and conversion, document cap table assumptions and dilution scenarios explicitly, and engage with investors transparently regarding the economic consequences of multiple conversion rounds. This transparency and procedural rigor reduce disputes and build investor confidence.

If you are a founder planning to issue SAFEs or convertible notes through a Cayman-domiciled company, an investor evaluating a SAFE investment, or managing cap table issues and multiple convertible instruments, Lexkara & Co provides expert guidance on SAFE and convertible note structuring, cap table management, and the interaction with Cayman company law. We work with founders and investors to clarify economic terms, optimize tax outcomes, and design investor protection mechanisms tailored to the company's stage and investor expectations.